Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

FDA approves Exelixis’ Cabometyx to treat advanced neuroendocrine tumours

Approximately 380,000 people in the US were affected by NETs in 2024

- PMLiVE

Brand building: pharma’s billion dollar blind spot

By Ed Corbett and Lucy Ireland

- PMLiVE

PMLiVE’s Top Pharma list – results and predictions for global drug sales

The list ranks the top companies in the pharmaceutical industry by their global sales, as well as by their revenues in the US, Europe and Japan

- PMLiVE

The future of heart health with AI-powered devices and treatment approaches

Artificial intelligence (AI) is revolutionising the field of cardiology, offering new hope for patients with cardiovascular disorders. AI is no longer futuristic, it’s a real-world tool, transforming patient care and...

Medscape Education

- PMLiVE

Merck granted EC approval for adult-specific pneumococcal vaccine Capvaxive

The vaccine protects against the serotypes responsible for the majority of adult invasive pneumococcal disease

Biogen Idec building

Biogen unveils plans for new global headquarters and R&D hub in US

The company is expecting to relocate its Cambridge-based employees to the new site in 2028

- PMLiVE

LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe

Approximately 125 million people worldwide are affected by some form of the inflammatory condition

- PMLiVE

PM Society announces launch of PMi Awards 2025

The event will take place on Thursday 11 September at the Brewery in London

- PMLiVE

Women in pharma

PME talks to Kay Wesley, CEO of Kanga Health, about her career in pharma

- PMLiVE

GSK’s antibiotic Blujepa granted FDA approval to treat urinary tract infections

Blujepa is the first in a new class of oral antibiotics for uncomplicated UTIs in nearly 30 years

- PMLiVE

J&J shares overall survival results for Rybrevant/Lazcluze combination in lung cancer

The regimen was approved by the MHRA earlier this month to treat EGFR-mutated NSCLC

- PMLiVE

FDA approves Soleno’s Vykat XR as first treatment for hyperphagia in Prader-Willi syndrome

The rare genetic disorder affects an estimated one in every 15,000 newborns in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links